Pathogenetic role of soluble intercellular adhesion molecule in inflammatory bowel diseases


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article is devoted to the topical problem of inflammatory bowel disease (IBD). Based on the analysis of the literature and the generalization of practical experience, an overview of current data on the IBD immunopathogenesis is presented. The issue of the role of adhesion molecules in ulcerative colitis (UC) and Crohn’s disease (CD) is still open. In recent years, special attention has been paid to blocking the active migration of leukocytes into the intestinal mucosa and key multifunctional signaling molecules - integrins, whose main role is to provide the mechanical contact of leukocytes with the endothelium. In this review, the authors focused on the structure and functions of the main classes of adhesion molecules, as well as changes in serum adhesive factor concentrations depending on the activity of the inflammatory process in the intestine in patients with UC and CD. This problem is poorly understood and requires further evaluation.

Full Text

Restricted Access

About the authors

Galina N. Tarasova

Rostov State Medical University

Email: doctor-gastro@yandex.ru
MD, Professor, Prof. at the Department of Propaedeutics of Internal Diseases

A. A Yakovlev

Rostov State Medical University

N. V Dobaeva

Rostov State Medical University

References

  1. Reinisch W., Hung K., Hassan-Zahraee M., Cataldi F. Targeting Endothelial Ligands: ICAM-1/ alicaforsen, MAdCAM-1. J Crohn's Colitis. 2018;12(2):669- 77. doi: 10.1093/ecco-jcc/ jjy059.
  2. Mitroulis I., Alexaki V.l., Kourtzelis I., et.al. Leukocyte integrins: Role in leukocyte recruitment and as therapeutic targets in inflammatory disease. Pharmacol Ther 2015;123-35. Doi: 10.1016/j. pharmthera.2014.11.008.
  3. Rivera-Nieves J. Strategies that Target Leukocyte Traffic in IBD: Recent Developments. Curr Opin Gastroenterol. 2015;31(6):441-48. doi: 10.1097/MOG.0000000000000218.
  4. Saruta M., Papadakis K.A. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases. Gastroenterol Clin North Am. 2014;43(3):581-601. Doi: 10.1016/ j.gtc.2014.05.012.
  5. Cernuda-Morollon E., Ridley A.J. Rho GTPases and leukocyte adhesion receptor expression and function in endothelial cells. Circ Res. 2006;98:757-67.
  6. Ашкинази В.И., Лебедев М.Ю., Руднев Е.И. Растворимые молекулы адгезии у детей с воспалительными заболеваниями кишечника. Цитокины и воспаление. 2015;3:24-29.
  7. O'Shea J.J., Ma A., Lipsky P. Cytokines and autoimmunity. Nat Rev Immunol. 2002;2:37-45.
  8. Ярилин А.А. Иммунология. Учебник. М.: ГЭОТАР-Медиа, 2010. 96 с. [Yarilin A.A. Immunology. Textbook. M.: GEOTAR-Media, 2010. 96p. (In Russ.)].
  9. Ашкинази В.И., Маянская И.В., Толкачева Н.И. Молекулы адгезии при деструктивно-воспалительном процессе в кишечнике у детей с язвенным колитом. Вопросы современной педиатрии. 2013;12(4):52-57.
  10. Panes J., Perry M.A., Anderson D.C., et al. Regional differences in constitutive and induced ICAM-1 expression in vivo. Am. J. Physiol. 1995;269:1955-64.
  11. Marshall B.T., Long M., Piper G.W., et al. Direct observation of catch bonds involving cell adhesion molecules. Nature. 2003;423(6936)190-93.
  12. Hogg N., Patzak I., Willenbrock F., et al. The insider's guide to leukocyte integrin signalling and function. Nat. Rev. Immunol. 2011;11(6):416-26. doi: 10.1038/nri2986.
  13. Humphries J.D., Byron A., Humphries M.J. Integrin ligands at a glance. J. Cell Sci. 2006;119: 3901-903.
  14. Carman C.V., Springer T.A. Integrin avidity regulation: are changes in affinity and conformation underemphasized? Curr Opin Cell Biol. 2003;15:547-56.
  15. Tiwari S., Askari J.A., Humphries M.J., et al. Divalent cations regulate the folding and activation status of integrins during their intracellular trafficking. J. Cell Sci. 2011;124:1672-80. Doi: 10.1242/ jcs.084483.
  16. Adamska I., Czerwionka-Szaflarska M., Kulwas A., et al. Adhesion molecules of immunoglobin super family in children and youth with inflammatory bowel disease. Pol Merkur Lekarski. 2009;26(152):101-4.
  17. Kunkel E.J., Ramos C.L., Steeber D.A., et al. The roles of L- selectin, beta 7 integrins, and P-selectin in leukocyte rolling and adhesion in high endothelial venules of Peyer's patches. J. Immunol. 1998;161:2449-56.
  18. Bamias G., Clark D. J., Rivera-Nieves J. Leukocyte Traffic Blockade in Inflammatory Bowel Disease. Curr Drug Targets. 2013;14(12):1490-500.
  19. Adams D.H., Eksteen B. Aberrant homing of mucosal T-cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol. 2006;6:244-51.
  20. Yacyshyn B.R., Lazarovits A., Tsai V., et al. Crohn's disease, ulcerative colitis, and normal intestinal lymphocytes express integrins in dissimilar patterns. Gastroenterology. 1994;107:1364-71.
  21. Vainer B., Nielsen O.H. Changed colonic profile of P-selectin, platelet- endothelial cell adhesion molecule-1 (PECAM-1), intercellular adhesion molecule-1 (ICAM-1), ICAM-2, and ICAM-3 in inflammatory bowel disease. Clin Exp Immunol. 2000;121:242-47.
  22. Magro F., Araujo F., Pereira P., et. al. Soluble selectins, sICAM, sVCAM, and angiogenic proteins in different activity groups of patients with inflammatory bowel disease. Dig Dis Sci. 2004;49(7-8):1265-74.
  23. Apostolaki M., Manoloukos M., Roulis M., et al. Role of beta7 integrin and the chemokine/ chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease. Gastroenterology 2008;134:2025-35. Doi: 10.1053/j. gastro.2008.02.085.
  24. Gorfu G., Rivera-Nieves J., Hoang S., et al. Beta7 integrin deficiency suppresses B. cell homing and attenuates chronic ileitis in SAMP1/YitFc mice. J. Immunol. 2010;185:5561-68. Doi: 10.4049/ jimmunol.0903938.
  25. Павленко В.В., Амирханова Л.З., Катаганова Г.А. Растворимые молекулы адгезии (ICAM-1, ICAM-2, l-селектин) при язвенном колите. Медицинский вестник Северного Кавказа. 2012;1:4-6.
  26. Лазебник Л. Б., Болдырева О.Н., Парфенов А.И. Роль молекул адгезии для оценки эффективности стандартной и биологической терапии боль -ных с болезнью Крона. Экспериментальная и клиническая гастроэнтерология. 2013;3:31-8.
  27. Павленко В.В., Катаганова Г.А., Амирханова Л.З. Новые возможности прогнозирования успеха биологической терапии при язвенном колите. Медицинский вестник Северного Кавказа. 2015;10(4):432-34.
  28. Jairath V., Khanna R., Feagan B.G. Alicaforsen for the treatment of inflammatory bowel disease. Expert. Opin. Investig. Drugs. 2017;6:1-7. doi: 10.1080/13543784.2017.1349753.
  29. Papamichael K., Rivals-Lerebours O., Billiet T., et al. Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab. J. Crohns Colitis. 2016;10(9):1015-23.
  30. Халиф И.Л., Шапина М.В. Применение ведолизумаба при воспалительных заболеваниях кишечника. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(6):92-100.
  31. Feagan B.G., Rutgeerts P., Sands B.E., et. al. Vedolizumab as induction and maintenance therapy for ul- cerative colitis. N. Engl J. Med. 2013;369(8):699-710. Doi: 10.1056/ NEJMoa1215734.
  32. Park S.C., Jeen Y.T. Anti-integrin therapy for inflammatory bowel disease. World J. Gastroenterol. 2018;24(17):1868-80. doi: 10.3748/wjg.v24. i17.1868.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies